COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countriesEng Hooi Tan, Daniel Prieto‐Alhambra, Heba Alghoul et al.|Lara D. Veeken|2021Cited by 53
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Arya Aminorroaya et al.|Journal of the American College of Cardiology|2024Cited by 33
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Lovedeep Singh Dhingra et al.|BMJ Medicine|2023Cited by 27
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDISKristin Kostka, Nicole G. Weiskopf, Talita Duarte‐Salles et al.|Clinical Epidemiology|2022Cited by 26
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and BevacizumabCindy X. Cai, Patrick Ryan, Akihiko Nishimura et al.|Ophthalmology Retina|2024Cited by 16